Answers are grounded in this paper and cite their sources.
The monoclonal antibody Palivizumab (PVZ) has been used for 25 years to prevent Respiratory Syncytial Virus (RSV) infections. Evidence regarding its performance in low and middle-income countries (LMIC) is scarce. In this uniquely conducted study in Brazil, we showed the real-life use of PVZ in a public health context.
No takes yet. Share an insight, caveat, or question.
Hig et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: